# Outcomes Mandate National Integration With Cannabis as Medicine

> **NCT03944447** · PHASE2 · UNKNOWN · sponsor: **OMNI Medical Services, LLC** · enrollment: 200000 (estimated)

## Conditions studied

- Chronic Pain
- Chronic Pain Syndrome
- Chronic Pain Due to Injury
- Chronic Pain Due to Trauma
- Fibromyalgia
- Seizures
- Hepatitis C
- Cancer
- Crohn Disease
- HIV/AIDS
- Multiple Sclerosis
- Traumatic Brain Injury
- Sickle Cell Disease
- Post Traumatic Stress Disorder
- Tourette Syndrome
- Ulcerative Colitis
- Glaucoma
- Epilepsy
- Inflammatory Bowel Diseases
- Parkinson Disease
- Amyotrophic Lateral Sclerosis
- Chronic Traumatic Encephalopathy
- Anxiety
- Depression
- Insomnia
- Autism
- Opioid-use Disorder
- Bipolar Disorder
- Covid19
- SARS-CoV Infection
- COVID-19
- Corona Virus Infection
- Coronavirus

## Interventions

- **DRUG:** Cannabis, Medical
- **DEVICE:** RYAH-Medtech Inhaler

## Key facts

- **NCT ID:** NCT03944447
- **Lead sponsor:** OMNI Medical Services, LLC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 200000 (ESTIMATED)
- **Last updated:** 2022-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944447, "Outcomes Mandate National Integration With Cannabis as Medicine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03944447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*